To this day, wet AMD is treated with anti-vascular endothelial growth factor (VEGF) drugs prescribed as first-line therapy, unlike dry AMD, for which there is no real effective treatment available in Europe. This evidence concerns the gene VEGFA and dry age related macular degeneration.